#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Dermatitis atopic Asthma Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Stress cardiomyopathy Alexander disease Gastrointestinal neuroendocrine tumour Adrenocortical carcinoma Hepatitis D Iron overload Neuroendocrine carcinoma of the skin Ovarian cancer stage III Gaucher's disease type III Nodal marginal zone B-cell lymphoma C3 glomerulopathy Kawasaki's disease Diabetes insipidus Acute hepatic failure Paraneoplastic neurological syndrome More trials…

    Learn about Rare Diseases

    Congenital hypotransferrinaemia – Basic Information Angiosarcoma – Basic Information Optic glioma – Trials in Disease Rhabdoid tumour – Trials in Disease Turner’s syndrome – Life with Disease Friedreich’s ataxia Pulmonary sarcoidosis – Diagnostics Bronchiolitis obliterans syndrome – Treatment Atypical haemolytic uraemic syndrome – Life with Disease Mucous membrane pemphigoid – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ammonium Chloride Bp Bupivacaine Hydrochloride Forimtamig Methylprednisolone Aceponate Vancomycin Ro7247669 Fadraciclib LTX-002 SODIUM Topotecan Hydrochloride ROPINIROLE HUPERZINE A Bi 764532 Carboplatin NALMEFENE HYDROCHLORIDE Glucose Monohydrate Dydrogesterone Cebsulfase Alfa Candesartan Cilexetil Nofazinlimab Temozolomide More therapies…

    Learn about Your Condition

    Takayasu's arteritis Ependymoma malignant Metastatic malignant melanoma Malignant melanoma stage III Prostate cancer Complex regional pain syndrome Radius fracture Biotinidase deficiency White matter lesion Neoplasm Tuberculosis Monkeypox EGFR gene mutation Lymphoedema Hyperadrenocorticism More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Essential thrombocythaemia

  • A study to evaluate the effectiveness and safety of iadademstat in adults with essential thrombocythemia who do not respond well to or cannot tolerate hydroxyurea

    Recruiting

    2 1 1
    Investigated Diseases:
    • Essential thrombocythaemia
    Investigated Drugs:
    • IADADEMSTAT
    Spain

  • Study on Apixaban, Rivaroxaban, and Aspirin for Preventing Blood Clots in Patients with JAK2V617F-Positive Myeloproliferative Neoplasms

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Essential thrombocythaemia
    • Myeloproliferative neoplasm
    • Chronic myeloid leukaemia
    Investigated Drugs:
    • Acetylsalicylic Acid
    • Apixaban
    • Rivaroxaban
    France

  • Study on the Safety of Bomedemstat for Patients with Myeloproliferative Neoplasms Who Participated in a Previous Bomedemstat Study

    Recruiting

    3 1 1
    Investigated Diseases:
    • Essential thrombocythaemia
    • Polycythaemia vera
    • Myelofibrosis
    Investigated Drugs:
    • Bomedemstat
    Italy

  • Study of Gandotinib for Patients with Myeloproliferative Neoplasms, Myelofibrosis, Essential Thrombocythemia, or Polycythemia Vera

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Myeloproliferative neoplasm
    • Essential thrombocythaemia
    • Polycythaemia vera
    Investigated Drugs:
    • Gandotinib
    Austria Germany Spain

  • Study of Ruxolitinib for Patients with High-Risk Polycythemia Vera or High-Risk Essential Thrombocythemia

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Ruxolitinib
    Germany

  • Study Comparing Bomedemstat and Hydroxycarbamide for Patients with Essential Thrombocythemia

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Essential thrombocythaemia
    Investigated Drugs:
    • Bomedemstat
    • Hydroxycarbamide
    Austria Denmark France Germany Hungary Italy +3
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!